Blood test could predict hodgkin lymphoma relapse
NCT ID NCT02815137
Summary
This study tested if a specific genetic change (XPO1 E571K mutation) found in the blood could be used to monitor patients with classical Hodgkin lymphoma. Researchers followed 137 adults with newly diagnosed Hodgkin lymphoma to see if detecting this mutation in blood tests could predict treatment outcomes better than standard PET scans. The goal was to understand if this blood marker could help doctors identify patients at higher risk of relapse after chemotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Henri Becquerel
Rouen, 76000, France
Conditions
Explore the condition pages connected to this study.